Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurology and Therapy
Published in: Neurology and Therapy 2/2023

Open Access 07-02-2023 | Multiple Sclerosis | REVIEW

Assisted Reproductive Techniques in Multiple Sclerosis: Recommendations from an Expert Panel

Authors: Celia Oreja-Guevara, Aintzane Rabanal, Corazón Hernández Rodríguez, Yolanda Aladro Benito, Mar Mendibe Bilbao, Inés Gónzalez-Suarez, José Luis Gómez-Palomares

Published in: Neurology and Therapy | Issue 2/2023

Login to get access

Abstract

Introduction

Multiple sclerosis (MS) is mainly diagnosed in women of reproductive age. However, there is a paucity of guidelines jointly prepared by neurologists and gynaecologists on managing women with MS and the desire for motherhood. Therefore, in this review we propose recommendations for such cases, with an particular focus on those requiring assisted reproductive techniques (ART).

Methods

A group of seven MS experts (4 neurologists and 3 gynaecologists) came together for three discussion sessions to achieve consensus.

Results

The recommendations reported here focus on the importance of early preconception counselling, the management of disease-modifying therapies before and during ART procedures, important considerations for women with MS regarding ART (intrauterine insemination, in vitro fertilisation and oocyte cryopreservation) and the paramount relevance of multidisciplinary units to manage these patients.

Conclusions

Early preconception consultations are essential to individualising pregnancy management in women with MS, and an early, well-planned, spontaneous pregnancy should be the aim whenever possible. The management of women with MS and the desire for motherhood by multidisciplinary units is warranted to ensure appropriate guidance through the entire pregnancy.
Literature
1.
Westerlind H, Boström I, Stawiarz L, et al. New data identify an increasing sex ratio of multiple sclerosis in Sweden. Mult Scler J. 2014;20(12):1578–83.CrossRef
2.
Amato MP, Portaccio E. Fertility, pregnancy and childbirth in patients with multiple sclerosis: Impact of disease-modifying drugs. CNS Drugs. 2015;29(3):207–20.PubMedCrossRef
3.
Masera S, Cavalla P, Prosperini L, et al. Parity is associated with a longer time to reach irreversible disability milestones in women with multiple sclerosis. Mult Scler J. 2015;21(10):1291–7.CrossRef
4.
Carvalho AT, Veiga A, Morgado J, et al. Esclerosis múltiple y decisión de la maternidad: estudio observacional en pacientes portuguesas [Multiple sclerosis and motherhood decision: an observational study on portuguese women]. Rev Neurol. 2014;59(12):537–42.PubMed
5.
Vukusic S, Confavreux C. Pregnancy and multiple sclerosis: the children of PRIMS. Clin Neurol Neurosurg. 2006;108(3):266–70.PubMedCrossRef
6.
Pozzilli C, Pugliatti M. An overview of pregnancy-related issues in patients with multiple sclerosis. Eur J Neurol. 2015;22(S2):34–9.PubMedCrossRef
7.
8.
Westbrook RH, Yeoman AD, Kriese S, Heneghan MA. Outcomes of pregnancy in women with autoimmune hepatitis. J Autoimmun. 2012;38(2–3):J239–44.PubMedCrossRef
9.
Poppe K, Glinoer D. Thyroid autoimmunity and hypothyroidism before and during pregnancy. Hum Reprod Update. 2003;9(2):149–61.PubMedCrossRef
10.
Hughes SE, Spelman T, Gray OM, et al. Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Mult Scler J. 2014;20(6):739–46.CrossRef
11.
Bove R, Alwan S, Friedman JM, et al. Management of multiple sclerosis during pregnancy and the reproductive years. Obstet Gynecol. 2014;124(6):1157–68.PubMedCrossRef
12.
Miller DH, Fazekas F, Montalban X, Reingold SC, Trojano M. Pregnancy, sex and hormonal factors in multiple sclerosis. Mult Scler J. 2014;20(5):527–36.CrossRef
13.
Kelly VM, Nelson LM, Chakravarty EF. Obstetric outcomes in women with multiple sclerosis and epilepsy. Neurology. 2009;73(22):1831–6.PubMedCrossRef
14.
Macdonald SC, McElrath TF, Hernández-Díaz S. Pregnancy outcomes in women with multiple sclerosis. Am J Epidemiol. 2019;188(1):57–66.PubMedCrossRef
15.
Hellwig K, Correale J. Artificial reproductive techniques in multiple sclerosis. Clin Immunol. 2013;149(2):219–24.PubMedCrossRef
16.
Hellwig K, Brzosko B, Airas L, Smith EK. Fertility and assisted reproductive techniques in women with MS. In: Houtchens MK, Dessa Sadovnick A, editors. Health issues in women with multiple sclerosis. Vienna: Springer Verlag GmbH Austria; 2017. p. 9–17.
17.
Fritz MA, Speroff L. Clinical gynecologic endocrinology and infertility. Philadelphia: Lippincott Williams & Wilkins; 2011.
18.
Pakenham KI, Fleming M. Relations between acceptance of multiple sclerosis and positive and negative adjustments. Psychol Health. 2011;26(10):1292–309.PubMedCrossRef
19.
Wilski M, Gabryelski J, Brola W, Tomasz T. Health-related quality of life in multiple sclerosis: links to acceptance, coping strategies and disease severity. Disabil Health J. 2019;12(4):608–14.PubMedCrossRef
20.
te Velde ER, Pearson PL. The variability of female reproductive ageing. Hum Reprod Update. 2002;8(2):141–54.CrossRef
21.
Hansen KR, Hodnett GM, Knowlton N, Craig LB. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil Steril. 2011;95(1):170–5.PubMedCrossRef
22.
Colligan E, Metzler A, Tiryaki E. Shared decision-making in multiple sclerosis. Mult Scler J. 2017;23(2):185–90.CrossRef
23.
Sociedad Española de Ginecología y Obstetricia. Guía de asistencia Práctica. Control prenatal del embarazo normal. [Practical assistance guidelines. Prenatal control of normal pregnancy]. Progresos Obstet Ginecol. 2018;61(5):510–27.
24.
van Houten ELAF, Themmen APN, Visser JA. Anti-Müllerian hormone (AMH): regulator and marker of ovarian function. Ann Endocrinol (Paris). 2010;71(3):191–7.PubMedCrossRef
25.
Vukusic S, Marignier R. Multiple sclerosis and pregnancy in the “treatment era.” Nat Rev Neurol. 2015;11(5):280–9.PubMedCrossRef
26.
Krysko KM, Bove R, Dobson R, Jokubaitis V, Hellwig K. Treatment of women with multiple sclerosis planning pregnancy. Curr Treat Options Neurol. 2021;23:11.PubMedPubMedCentralCrossRef
27.
Bsteh G, Hegen H, Riedl K, et al. Estimating risk of multiple sclerosis disease reactivation in pregnancy and postpartum: the VIPRiMS score. Front Neurol. 2022;12:766956.
28.
Doosti R, Togha M, Naser Moghadasi A, et al. Evaluation of the risk of cervical cancer in patients with multiple sclerosis treated with cytotoxic agents: a cohort study. Curr J Neurol. 2018;17(2):64–70.
29.
Rauma I, Mustonen T, Seppä JM, et al. Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients. J Neurol. 2022;269(2):824–35.PubMedCrossRef
30.
Barnett R, Banks N, Decherney AH. Endometriosis and fertility preservation. Clin Obstet Gynecol. 2017;60(3):517–23.PubMedCrossRef
31.
Coyle PK, Oh J, Magyari M, Oreja-Guevara C, Houtchens M. Management strategies for female patients of reproductive potential with multiple sclerosis: an evidence-based review. Mult Scler Relat Disord. 2019;32:54–63.PubMedCrossRef
32.
33.
34.
Galati A, McElrath T, Bove R. Use of B-cell—depleting therapy in women of childbearing potential with multiple sclerosis and neuromyelitis optica spectrum disorder. Neurol Clin Pract. 2022;12(2):154–63.PubMedPubMedCentralCrossRef
35.
Bahadur G, Homburg R, Bosmans JE, et al. Observational retrospective study of UK national success, risks and costs for 319,105 IVF/ICSI and 30,669 IUI treatment cycles. BMJ Open. 2020;10(3): e034566.PubMedPubMedCentralCrossRef
36.
Oseguera-López I, Ruiz-Díaz S, Ramos-Ibeas P, Pérez-Cerezales S. Novel techniques of sperm selection for improving IVF and ICSI outcomes. Front Cell Dev Biol. 2019;7:298.
37.
Pandian Z, Templeton A, Serour G, Bhattacharya S. Number of embryos for transfer after IVF and ICSI: a Cochrane review. Hum Reprod. 2005;20(10):2681–7.PubMedCrossRef
38.
Practice Committee of the American Society for Reproductive Medicine. Multiple gestation associated with infertility therapy: an American Society for Reproductive Medicine Practice Committee opinion. Fertil Steril. 2012;97(4):825–34.CrossRef
39.
Vlaisavljevic V, Apter S, Capalbo A, et al. The Maribor consensus: report of an expert meeting on the development of performance indicators for clinical practice in ART. Hum Reprod Open. 2021;2021(3):hoab022.PubMedPubMedCentralCrossRef
40.
Lewis V. Vademecum. Reproductive endocrinology and infertility. Austin: Landes Bioscience; 2007.
41.
Al-Inany HG, Youssef MAFM, Aboulghar M, et al. GnRH antagonists are safer than agonists: an update of a Cochrane review. Hum Reprod Update. 2011;17(4):435.PubMedCrossRef
42.
Bove R, Rankin K, Lin C, et al. Effect of assisted reproductive technology on multiple sclerosis relapses: case series and meta-analysis. Mult Scler J. 2020;26(11):1410–9.CrossRef
43.
Mainguy M, Tillaut H, Degremont A, et al. Assessing the risk of relapse requiring corticosteroids after in vitro fertilization in women with multiple sclerosis. Neurology. 2022;99(17):e1916–25.
44.
Hellwig K, Schimrigk S, Beste C, Müller T, Gold R. Increase in relapse rate during assisted reproduction technique in patients with multiple sclerosis. Eur Neurol. 2009;61(2):65–8.PubMedCrossRef
45.
Michel L, Foucher Y, Vukusic S, et al. Increased risk of multiple sclerosis relapse after in vitro fertilisation. J Neurol Neurosurg Psychiatry. 2012;83(8):796–802.PubMedCrossRef
46.
Sparaco M, Bonavita S. The role of sex hormones in women with multiple sclerosis: from puberty to assisted reproductive techniques. Front Neuroendocrinol. 2021;60:100889.PubMedCrossRef
47.
Taylor TH, Wright G, Jones-Colon S, et al. Comparison of ICSI and conventional IVF in patients with increased oocyte immaturity. Reprod Biomed Online. 2008;17(1):46–52.PubMedCrossRef
48.
Jungheim ES, Meyer MF, Broughton DE. Best practices for controlled ovarian stimulation in in vitro fertilization. Semin Reprod Med. 2015;33(2):77–82.PubMedPubMedCentralCrossRef
49.
Alper MM, Fauser BC. Ovarian stimulation protocols for IVF: is more better than less? Reprod Biomed Online. 2017;34(4):345–53.PubMedCrossRef
50.
51.
Chambers GM, Paul RC, Harris K, et al. Assisted reproductive technology in Australia and New Zealand: cumulative live birth rates as measures of success. Med J Aust. 2017;207(3):114–8.PubMedCrossRef
52.
Esteves SC, Roque M, Bedoschi GM, et al. Defining low prognosis patients undergoing assisted reproductive technology: POSEIDON criteria-the why. Front Endocrinol (Lausanne). 2018;9(AUG):1–10.
53.
Whelan JG III, Vlahos NF. The ovarian hyperstimulation syndrome. Fertil Steril. 2000;73(5):883–96.PubMedCrossRef
54.
Balaban B, Urman B. Effect of oocyte morphology on embryo development and implantation. Reprod Biomed Online. 2006;12(5):608–15.PubMedCrossRef
55.
Wong KM, Mastenbroek S, Repping S. Cryopreservation of human embryos and its contribution to in vitro fertilization success rates. Fertil Steril. 2014;102(1):19–26.PubMedCrossRef
56.
Maheshwari A, Mclernon D, Bhattacharya S. Cumulative live birth rate: time for a consensus? Hum Reprod. 2015;30(12):2703–7.PubMed
57.
Veleva Z, Vilska S, Hydén-Granskog C, et al. Elective single embryo transfer in women aged 36–39 years. Hum Reprod. 2006;21(8):2098–102.PubMedCrossRef
58.
Thöne J, Thiel S, Gold R, Hellwig K. Expert opinion on drug safety treatment of multiple sclerosis during pregnancy—safety considerations. Expert Opin Drug Saf. 2017;16(5):523–34.PubMedCrossRef
59.
Prévinaire JG, Lecourt G, Soler JM, Denys P. Sexual disorders in men with multiple sclerosis: evaluation and management. Ann Phys Rehabil Med. 2014;57(5):329–36.PubMedCrossRef
60.
Fode M, Ohl DA, Sønksen J. A step-wise approach to sperm retrieval in men with neurogenic anejaculation. Nat Rev Urol. 2015;12:607–16.PubMedCrossRef
61.
Specchia C, Baggiani A, Immediata V, et al. Oocyte cryopreservation in oncological patients: eighteen years experience of a tertiary care referral center. Front Endocrinol (Lausanne). 2019;10:600.PubMedCrossRef
62.
Llarena NC, Falcone T, Flyckt RL. Fertility preservation in women with endometriosis. Clin Med Insights Reprod Health. 2019;13:1–8.CrossRef
63.
Somigliana E, Viganò P, Filippi F, et al. Fertility preservation in women with endometriosis: for all, for some, for none? Hum Reprod. 2015;30(6):1280–6.PubMedCrossRef
64.
Mathieu E, Ferrier C, Zacharopoulou C, et al. Outcomes of fertility preservation in women with endometriosis: comparison of progestin-primed ovarian stimulation versus antagonist protocols. J Ovarian Res. 2020;13:18.CrossRef
65.
Stoop D, Maes E, Polyzos NP, et al. Does oocyte banking for anticipated gamete exhaustion influence future relational and reproductive choices? A follow-up of bankers and non-bankers. Hum Reprod. 2015;30(2):338–44.PubMedCrossRef
66.
67.
Doyle JO, Richter KS, Lim J, et al. Successful elective and medically indicated oocyte vitrification and warming for autologous in vitro fertilization, with predicted birth probabilities for fertility preservation according to number of cryopreserved oocytes and age at retrieval. Fertil Steril. 2016;105(2):459-466.e2.PubMedCrossRef
68.
Soelberg Sorensen P, Giovannoni G, Montalban X, et al. The multiple sclerosis care unit. Mult Scler J. 2019;25(5):627–36.CrossRef
69.
Morgan-Followell BN, Nicholas JA, Weisleder P. Reproductive issues in women with multiple sclerosis: ethical considerations. Neurol Pregnancy. 2014;20(1):177–80.
70.
Vrtačnik Bokal E, Vrtačnik U. Impact of multiple sclerosis on infertility and impact of infertility treatments on multiple sclerosis relapses in slovenia: medical outline, legal and ethical outcomes. Med Law Soc. 2020;13(2):153–72.CrossRef
71.
Payne D, McPherson KM. Becoming mothers. Multiple sclerosis and motherhood: a qualitative study. Disabil Rehabil. 2010;32(8):629–38.PubMedCrossRef
72.
73.
Riis Jølving L, Due Larsen M, Fedder J, Mertz NB. Live birth in women with multiple sclerosis receiving assisted reproduction. Reprod Biomed Online. 2020;40(5):711–8.CrossRef
Metadata
Title
Assisted Reproductive Techniques in Multiple Sclerosis: Recommendations from an Expert Panel
Authors
Celia Oreja-Guevara
Aintzane Rabanal
Corazón Hernández Rodríguez
Yolanda Aladro Benito
Mar Mendibe Bilbao
Inés Gónzalez-Suarez
José Luis Gómez-Palomares
Publication date
07-02-2023
Publisher
Springer Healthcare
Published in
Neurology and Therapy / Issue 2/2023
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI
https://doi.org/10.1007/s40120-023-00439-y

Other articles of this Issue 2/2023

Neurology and Therapy 2/2023 Go to the issue

REVIEW

The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus

ORIGINAL RESEARCH

Discrete Choice Experiment to Understand Japanese Patients’ and Physicians’ Preferences for Preventive Treatments for Migraine

Correction

Correction to: Off-time Treatment Options for Parkinson’s Disease

ORIGINAL RESEARCH

Characterization of Disease Severity and Stability in NMOSD: A Global Clinical Record Review with Patient Interviews

ORIGINAL RESEARCH

Understanding Treatment Decisions in Neuromyelitis Optica Spectrum Disorder: A Global Clinical Record Review with Patient Interviews

COMMENTARY

Unmet Needs in Preventive Treatment of Migraine